SRGN and astrocytoma (excluding glioblastoma): We performed tissue analysis of serglycin expression in human low-grade (astrocytomas, oligoastrocytomas and oligodendrogliomas grade II, n = 87) and high-grade glioma (anaplastic gliomas and glioblastomas, n = 101) TMAs.